Excerpt of Foreign Ministry Regular Press Conference on November 12, 2020

Q: According to reports, Brazil's National Health Surveillance Agency (Anvisa) released a statement on November 11 announcing that after evaluating the data provided by Butantan Institute, it believes that there are sufficient reasons to authorize the resumption of Sinovac's clinical trials on the same day. Does China have a comment?

A: We have taken note of the statement from the Brazilian authority as well as Sinovac's response. We are glad to see the resumption of phase III clinical trials of the COVID-19 vaccine.

In the process of vaccine research and development, the Chinese side attaches paramount importance to safety and efficacy and strictly complies with international standards and relevant laws and regulations. Chinese companies have been sparing no efforts in advancing vaccine R&D in strict accordance with scientific laws and regulatory requirements. Four Chinese vaccines are in phase III clinical trials in multiple countries, indicating preliminarily a good safety profile. China's vaccine R&D progress has been commended by many countries.

China and Brazil have conducted good cooperation in fighting COVID-19. We are confident that relevant cooperation will contribute to vanquishing the virus in China, Brazil and the rest of the world.

Suggest to a Friend:   
Print